These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
330 related articles for article (PubMed ID: 29940591)
1. Circulating Tumor DNA as a Sensitive Marker in Patients Undergoing Irreversible Electroporation for Pancreatic Cancer. Lin M; Alnaggar M; Liang S; Chen J; Xu K; Dong S; Du D; Niu L Cell Physiol Biochem; 2018; 47(4):1556-1564. PubMed ID: 29940591 [TBL] [Abstract][Full Text] [Related]
3. Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer. Hadano N; Murakami Y; Uemura K; Hashimoto Y; Kondo N; Nakagawa N; Sueda T; Hiyama E Br J Cancer; 2016 Jun; 115(1):59-65. PubMed ID: 27280632 [TBL] [Abstract][Full Text] [Related]
4. Longitudinal analysis of cell-free mutated KRAS and CA 19-9 predicts survival following curative resection of pancreatic cancer. Hussung S; Akhoundova D; Hipp J; Follo M; Klar RFU; Philipp U; Scherer F; von Bubnoff N; Duyster J; Boerries M; Wittel U; Fritsch RM BMC Cancer; 2021 Jan; 21(1):49. PubMed ID: 33430810 [TBL] [Abstract][Full Text] [Related]
5. Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma. Strijker M; Soer EC; de Pastena M; Creemers A; Balduzzi A; Beagan JJ; Busch OR; van Delden OM; Halfwerk H; van Hooft JE; van Lienden KP; Marchegiani G; Meijer SL; van Noesel CJ; Reinten RJ; Roos E; Schokker S; Verheij J; van de Vijver MJ; Waasdorp C; Wilmink JW; Ylstra B; Besselink MG; Bijlsma MF; Dijk F; van Laarhoven HW Int J Cancer; 2020 Mar; 146(5):1445-1456. PubMed ID: 31340061 [TBL] [Abstract][Full Text] [Related]
6. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer. Patel H; Okamura R; Fanta P; Patel C; Lanman RB; Raymond VM; Kato S; Kurzrock R J Hematol Oncol; 2019 Dec; 12(1):130. PubMed ID: 31801585 [TBL] [Abstract][Full Text] [Related]
7. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer. Lee B; Lipton L; Cohen J; Tie J; Javed AA; Li L; Goldstein D; Burge M; Cooray P; Nagrial A; Tebbutt NC; Thomson B; Nikfarjam M; Harris M; Haydon A; Lawrence B; Tai DWM; Simons K; Lennon AM; Wolfgang CL; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P Ann Oncol; 2019 Sep; 30(9):1472-1478. PubMed ID: 31250894 [TBL] [Abstract][Full Text] [Related]
8. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer. Bernard V; Kim DU; San Lucas FA; Castillo J; Allenson K; Mulu FC; Stephens BM; Huang J; Semaan A; Guerrero PA; Kamyabi N; Zhao J; Hurd MW; Koay EJ; Taniguchi CM; Herman JM; Javle M; Wolff R; Katz M; Varadhachary G; Maitra A; Alvarez HA Gastroenterology; 2019 Jan; 156(1):108-118.e4. PubMed ID: 30240661 [TBL] [Abstract][Full Text] [Related]
9. Detection of circulating tumor DNA without a tumor-informed search using next-generation sequencing is a prognostic biomarker in pancreatic ductal adenocarcinoma. Affolter KE; Hellwig S; Nix DA; Bronner MP; Thomas A; Fuertes CL; Hamil CL; Garrido-Laguna I; Scaife CL; Mulvihill SJ; Underhill HR Neoplasia; 2021 Sep; 23(9):859-869. PubMed ID: 34298235 [TBL] [Abstract][Full Text] [Related]
10. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer. Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T PLoS One; 2019; 14(12):e0227366. PubMed ID: 31891652 [TBL] [Abstract][Full Text] [Related]
11. Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer. Groot VP; Mosier S; Javed AA; Teinor JA; Gemenetzis G; Ding D; Haley LM; Yu J; Burkhart RA; Hasanain A; Debeljak M; Kamiyama H; Narang A; Laheru DA; Zheng L; Lin MT; Gocke CD; Fishman EK; Hruban RH; Goggins MG; Molenaar IQ; Cameron JL; Weiss MJ; Velculescu VE; He J; Wolfgang CL; Eshleman JR Clin Cancer Res; 2019 Aug; 25(16):4973-4984. PubMed ID: 31142500 [TBL] [Abstract][Full Text] [Related]
12. Clinical Implications of Pre- and Postoperative Circulating Tumor DNA in Patients with Resected Pancreatic Ductal Adenocarcinoma. Yamaguchi T; Uemura K; Murakami Y; Kondo N; Nakagawa N; Okada K; Seo S; Hiyama E; Takahashi S; Sueda T Ann Surg Oncol; 2021 Jun; 28(6):3135-3144. PubMed ID: 33128119 [TBL] [Abstract][Full Text] [Related]
13. Detection of Circulating Tumor DNA in Patients with Pancreatic Cancer Using Digital Next-Generation Sequencing. Macgregor-Das A; Yu J; Tamura K; Abe T; Suenaga M; Shindo K; Borges M; Koi C; Kohi S; Sadakari Y; Dal Molin M; Almario JA; Ford M; Chuidian M; Burkhart R; He J; Hruban RH; Eshleman JR; Klein AP; Wolfgang CL; Canto MI; Goggins M J Mol Diagn; 2020 Jun; 22(6):748-756. PubMed ID: 32205290 [TBL] [Abstract][Full Text] [Related]
14. Improved Assessment of Response Status in Patients with Pancreatic Cancer Treated with Neoadjuvant Therapy using Somatic Mutations and Liquid Biopsy Analysis. Yin L; Pu N; Thompson E; Miao Y; Wolfgang C; Yu J Clin Cancer Res; 2021 Feb; 27(3):740-748. PubMed ID: 33082211 [TBL] [Abstract][Full Text] [Related]
15. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients. Allenson K; Castillo J; San Lucas FA; Scelo G; Kim DU; Bernard V; Davis G; Kumar T; Katz M; Overman MJ; Foretova L; Fabianova E; Holcatova I; Janout V; Meric-Bernstam F; Gascoyne P; Wistuba I; Varadhachary G; Brennan P; Hanash S; Li D; Maitra A; Alvarez H Ann Oncol; 2017 Apr; 28(4):741-747. PubMed ID: 28104621 [TBL] [Abstract][Full Text] [Related]
16. Monitoring of circulating tumour DNA in advanced pancreatic ductal adenocarcinoma predicts clinical outcome and reveals disease progression earlier than radiological imaging. Edland KH; Tjensvoll K; Oltedal S; Dalen I; Lapin M; Garresori H; Glenjen N; Gilje B; Nordgård O Mol Oncol; 2023 Sep; 17(9):1857-1870. PubMed ID: 37341038 [TBL] [Abstract][Full Text] [Related]
17. Circulating tumor DNA as a prognostic indicator in resectable pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. Lee JS; Rhee TM; Pietrasz D; Bachet JB; Laurent-Puig P; Kong SY; Takai E; Yachida S; Shibata T; Lee JW; Park HC; Zang DY; Jeon K; Lee J; Kim M; Kim HS; Kang HJ; Lee YK Sci Rep; 2019 Nov; 9(1):16971. PubMed ID: 31740696 [TBL] [Abstract][Full Text] [Related]
18. Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up: A systematic review. Abdallah R; Taly V; Zhao S; Pietrasz D; Bachet JB; Basile D; Mas L; Zaanan A; Laurent-Puig P; Taieb J Cancer Treat Rev; 2020 Jul; 87():102028. PubMed ID: 32485509 [TBL] [Abstract][Full Text] [Related]